Skeletal Diseases & Injuries

Arthritis

Arthritis is caused by inflammation in your joints. It causes pain and stiffness in affected joints, which usually worsens with age. There are two common forms of arthritis osteoarthritis and rheumatoid arthritis.

Osteoarthritis is the most common form of arthritis that occurs when cartilage, the connective tissue found between bones, breaks down. Rheumatoid arthritis on the other hand is an autoimmune disease, when the immune system attacks and destroys healthy tissue. In people with rheumatoid arthritis, the immune system attacks and breaks down the smooth lining in a joint (called the synovium) causing pain and inflammation.

Due to their regenerative capabilities stem cells are being explored for treating arthritis. The hope is stem cells can regenerate the tissues that are affected by arthritis.

TRIAL HYPOTHESIS CLINICAL TRIAL ID
Looking at the safety and efficacy of allogeneic (from a donor) mesenchymal stem cell infusion to treat new onset Rheumatoid Arthritis. NCT03186417 National Institute of Arthritis and Musculoskeletal and Skin Diseases, USA
Can allogeneic umbilical tissue-derived stem cells be used to induce remission of rheumatoid arthritis in patients that don’t respond to standard anti-rheumatoid drug therapy? NCT01985464 Stem Cell Institute, Panama
Exploring the use of autologous adipose-derived mesenchymal stem cells (HD-adMSCs) as a possible treatment for rheumatoid arthritis. NCT03691909 Hope Bioscience, Texas, USA
Looking at the safety and efficacy of allogeneic (from a donor) mesenchymal stem cell infusion to treat new onset Rheumatoid Arthritis. NCT03186417 National Institute of Arthritis and Musculoskeletal and Skin Diseases, USA
Safety and effectiveness of using amniotic and umbilical cord tissue to treat the following conditions: orthopaedic, neurological, urologic, autoimmune, renal, cardiac and pulmonary. NCT03899298 R3 Stem Cell, USA
Tolerability of umbilical cord tissue derived mesenchymal stem cell product BX-U001 for treating refractory rheumatoid arthritis NCT03828344 Baylx Inc, California
How does implanting allogeneic mesenchymal stem cells derived umbilical cord Wharton’s Jelly influence the pain and functioning in patients with knee osteoarthritis? NCT03337243 Scott Medical Health Center, Pittsburgh, Pennsylvania
Is there a maximum tolerated dose umbilical cord derived mesenchymal stem cells that can be used to treat knee osteoarthritis? NCT03357770 Peking University People’s Hospital
Can allogeneic umbilical cord mesenchymal stem cells be used to manage osteoarthritis? NCT03800810 Indonesia University
Multicenter trial of stem cell therapy for osteoarthritis NCT03818737 Emory University

Spinal Cord Injury

Damage to the spinal cord, which changes it functions either temporarily or permanently results in spinal cord injuries. Depending on where the injury happens it can be classified a complete injury, where all sensation and muscle function is lost, or incomplete, where some nerve signals can travel past the injured area of the spinal cord. Common symptoms associated with spinal cord injuries include loss of sensation and muscle function to part of the body below the level of injury.

In 2019, Japan became the first country in the world to approve using stem cells to treat spinal cord injuries.

TRIAL HYPOTHESIS CLINICAL TRIAL ID
Exploring the safety and effectiveness of injecting allogeneic (from donor) umbilical cord derived mesenchymal stem cells into the spinal canal to treat patients with late stage chronic spinal cord injury. NCT03505034 West China Hospital & Shanghai East Hospital
Exploring the safety and effectiveness of injecting allogeneic (from donor) umbilical cord derived mesenchymal stem cells into the spinal canal to treat patients with sub-acute spinal cord injury. NCT03521336 West China Hospital & Shanghai East Hospital
Exploring the safety and effectiveness of injecting allogeneic (from donor) umbilical cord derived mesenchymal stem cells into the spinal canal to treat patients with early stage chronic spinal cord injury. NCT03521323 West China Hospital & Shanghai East Hospital
Can mesenchymal stem cells derived from fat tissue be safely administered into the cerebrospinal fluid (CSF) of patients with spinal cord injury? NCT03308565 Mayo Clinic, USA
Safety study of transplanting human spinal cord-derived neural stem cells to treat chronic spinal cord injury. NCT01772810 Neuralstem Inc., Maryland, USA
Potential benefits of using autologous (from donor) bone marrow derived stem cells to treat spinal cord injury with impaired motor or sensory function. NCT03225625 The Healing Institute, Florida, USA
Safety and tolerability of FAB117-HC (product containing human allogeneic adipose derived adult mesenchymal stem cells expanded and pulsed by H2O2 in culture) administered at a single-time point to patients with spinal cord injury. NCT02917291 Histocell S.L., Spain
How does direct transplantation (through surgery) of bone marrow-derived mesenchymal stem cell (cellgram-spine) affect injured spinal cords? NCT01676441 Pharmicell Co., Ltd., South Korea
Use of autologous (from patient) bone marrow mesenchymal stem cell transplant to treat patients with chronic and complete spinal cord injury. NCT02574585 Hospital Sao Rafael, Brazil

Cartilage Repair

Cartilage is connective tissue that provides rubber-like protection to the ends of our bones at the joints. It’s also a structural component of the ear, the nose, airways, disks in our spinal cord and the rib cage. It is made of specialized cells known as chondrocytes.

When the cartilage between bones wear off it can lead to conditions like osteoarthritis and damage to joints. Stem cells are being looked as a potential therapy to induce regeneration of cartilage.

TRIAL HYPOTHESIS CLINICAL TRIAL ID
The efficacy and safety of transplanting umbilical cord mesenchymal stem cells in patients with knee cartilage damage. NCT02776943 South China Research Center for Stem Cell and Regenerative Medicine
The efficacy and safety of using umbilical cord mesenchymal stem cells to treat articular cartilage defect of the knee. NCT02291926 The Fifth Affiliated Hospital of Guangzhou Medical University, China
Study of allogeneic-unrelated umbilical cord blood-derived mesenchymal stem cell product (Cartistem®) in patients with articular cartilage defect or injury. NCT01041001 Medipost Co Ltd., South Korea
A long term follow-up study looking at the safety and effectiveness of CARTISTEM®, in repair of cartilage injury or defects, compared with microfracture. NCT01626677 Medipost Co Ltd., South Korea